| Erythropoiesis Stimulating Agent (ESA) use, by DOPPS country and cross-section |
| N Ptnts | Wgtd % | Total N | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 7,940 | 87.0% | 9,117 |
| All | DOPPS 2(2002) | |||
| DOPPS 3(2006) | 7,745 | 90.6% | 8,552 | |
| DOPPS 3(2007) | 6,861 | 89.3% | 7,672 | |
| AusNZ | DOPPS 2(2002) | 446 | 86.8% | 513 |
| DOPPS 3(2006) | 479 | 90.8% | 527 | |
| DOPPS 3(2007) | 434 | 88.9% | 486 | |
| Belgium | DOPPS 2(2002) | 506 | 94.3% | 538 |
| DOPPS 3(2006) | 487 | 95.9% | 509 | |
| DOPPS 3(2007) | 391 | 92.6% | 420 | |
| Canada | DOPPS 2(2002) | 555 | 92.2% | 601 |
| DOPPS 3(2006) | 525 | 95.0% | 551 | |
| DOPPS 3(2007) | 420 | 93.4% | 445 | |
| France | DOPPS 2(2002) | 434 | 82.1% | 528 |
| DOPPS 3(2006) | 512 | 93.0% | 551 | |
| DOPPS 3(2007) | 500 | 91.4% | 543 | |
| Germany | DOPPS 2(2002) | 496 | 86.8% | 571 |
| DOPPS 3(2006) | 518 | 89.3% | 583 | |
| DOPPS 3(2007) | 565 | 90.7% | 623 | |
| Italy | DOPPS 2(2002) | 478 | 82.9% | 576 |
| DOPPS 3(2006) | 469 | 88.1% | 533 | |
| DOPPS 3(2007) | 468 | 86.3% | 542 | |
| Japan | DOPPS 2(2002) | 1,456 | 80.4% | 1,805 |
| DOPPS 3(2006) | 1,531 | 83.4% | 1,832 | |
| DOPPS 3(2007) | 1,549 | 83.3% | 1,867 | |
| Spain | DOPPS 2(2002) | 549 | 89.5% | 613 |
| DOPPS 3(2006) | 619 | 93.0% | 666 | |
| DOPPS 3(2007) | 512 | 92.2% | 555 | |
| Sweden | DOPPS 2(2002) | 508 | 92.9% | 547 |
| DOPPS 3(2006) | 516 | 95.4% | 542 | |
| DOPPS 3(2007) | 477 | 93.2% | 511 | |
| UK | DOPPS 2(2002) | 521 | 92.2% | 565 |
| DOPPS 3(2006) | 411 | 91.7% | 445 | |
| DOPPS 3(2007) | 324 | 89.8% | 351 | |
| US | DOPPS 2(2002) | 1,991 | 88.1% | 2,260 |
| DOPPS 3(2006) | 1,678 | 92.8% | 1,813 | |
| DOPPS 3(2007) | 1,221 | 91.7% | 1,329 | |
| Use of any ESA in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.